Total Funding
77
25
Total FundingSeries A raised
Growth Score
-5 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
1143157
RapidScan is improving patient care surrounding the diagnosis of cardiac disease by reducing time and cost while increasing efficiency.
- Daniel Spiegelman: Founder
- Louis Lange: FounderPast Role: CV Therapeutics, Co - Founder / Chairman / CEO
About the Company
Rapidscan Pharma Solutions (RPS, Inc.) was formed in 2010 by leading members of the team that discovered and developed regadenoson, a new pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease. RPS, Inc. has licensed the rights to sell regadenoson in Europe and other select territories.
Today, there
are over 15M people in Europe with coronary artery disease, of which 1.5M patients undergo a myocardial perfusion imaging (MPI) procedure in the diagnosis of coronary artery disease (CAD).
